P532 Delay of maintenance infliximab increases the risk of relapse in Crohn’s disease during the COVID-19 pandemic

Abstract Background Scheduled maintenance infliximab (IFX) therapies were frequently delayed during the COVID-19 pandemic. The unusual situation allowed us to study the influence of decreased treatment adherence on Crohn’s disease (CD). This retrospective study aimed to evaluate the effect of IFX delay on relapse in Crohn’s disease (CD) patients. Methods 166 CD patients with maintenance IFX between January 25, 2020, and April 25, 2020, were retrospectively enrolled. Demographic and clinical characteristics were recorded. Relapse was defined as clinical disease relapse or biochemical disease relapse (C-reactive protein (CRP) level ≥5 mg/L without other, non-IBD related explanation). Associations between relapse and IFX delay were analyzed. Results A retrospective cohort study was conducted, including 166 CD patients receiving maintenance IFX infusion during the COVID-19 pandemic. Of all, 135 (81.3%) had delayed their IFX infusion. Only 31 (18.7%) followed the schedule infusion during the COVID-19 pandemic. The median time of the IFX delay was 18.6±17.1 days. The relapse rate in the IFX-delay group was significantly higher than the group without delay (25.9% versus 5.5%, P＜0.02). During a median IFX delay interval of 46 days (95% CI 20.9–71.1), the ratio of relapse increased with the increase of IFX delay intervals. Delay interval had a cumulative effect on disease recurrence. We proposed interval prolongation resulted in a significant IFX trough concentration reduction. Conclusion Our study provided real-world evidence of influence on relapse of IFX delay in CD patients undergone maintenance therapy. It might help the IBD specialists arrange reasonable IFX treatment intervals for patients.

Download Full-text

Ornidazole for Prophylaxis of Postoperative Crohn's Disease Recurrence: A Randomized, Double-Blind, Placebo-Controlled Trial

Yearbook of Gastroenterology ◽

10.1016/s0739-5930(08)70327-1 ◽

2006 ◽

Vol 2006 ◽

pp. 117-118

Author(s):

G.R. Lichtenstein

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Trial ◽

Disease Recurrence ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Granulomas as a Predictor of Disease Recurrence in Crohn's Disease

Endoscopy ◽

10.1055/s-2006-956802 ◽

2006 ◽

Vol 38 (11) ◽

Author(s):

G Cullen ◽

A O'Toole ◽

L Brennan ◽

JM Hyland ◽

K Sheahan ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Disease Recurrence

Download Full-text

Faculty Opinions recommendation of Infliximab prevents Crohn's disease recurrence after ileal resection.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1148077.622680 ◽

2009 ◽

Author(s):

Themistocles Dassopoulos

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Disease Recurrence ◽

Ileal Resection

Download Full-text

Anastomotic Ulcers After Ileocolic Resection for Crohn’s Disease Are Common and Predict Recurrence

Inflammatory Bowel Diseases ◽

10.1093/ibd/izz224 ◽

2019 ◽

Vol 26 (7) ◽

pp. 1050-1058 ◽

Cited By ~ 3

Author(s):

Robert P Hirten ◽

Ryan C Ungaro ◽

Daniel Castaneda ◽

Sarah Lopatin ◽

Bruce E Sands ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Multivariable Analysis ◽

Disease Recurrence ◽

Ileocolic Resection ◽

Anastomotic Ulcer ◽

Endoscopic Recurrence ◽

Academic Center ◽

Endoscopic Remission ◽

The Impact

Abstract Background Crohn’s disease recurrence after ileocolic resection is common and graded with the Rutgeerts score. There is controversy whether anastomotic ulcers represent disease recurrence and should be included in the grading system. The aim of this study was to determine the impact of anastomotic ulcers on Crohn’s disease recurrence in patients with prior ileocolic resections. Secondary aims included defining the prevalence of anastomotic ulcers, risk factors for development, and their natural history. Methods We conducted a retrospective cohort study of patients undergoing an ileocolic resection between 2008 and 2017 at a large academic center, with a postoperative colonoscopy assessing the neoterminal ileum and ileocolic anastomosis. The primary outcome was disease recurrence defined as endoscopic recurrence (>5 ulcers in the neoterminal ileum) or need for another ileocolic resection among patients with or without an anastomotic ulcer in endoscopic remission. Results One hundred eighty-two subjects with Crohn’s disease and an ileocolic resection were included. Anastomotic ulcers were present in 95 (52.2%) subjects. No factors were associated with anastomotic ulcer development. One hundred eleven patients were in endoscopic remission on the first postoperative colonoscopy. On multivariable analysis, anastomotic ulcers were associated with disease recurrence (adjusted hazard ratio [aHR] 3.64; 95% CI, 1.21–10.95; P = 0.02). Sixty-six subjects with anastomotic ulcers underwent a second colonoscopy, with 31 patients (79.5%) having persistent ulcers independent of medication escalation. Conclusion Anastomotic ulcers occur in over half of Crohn’s disease patients after ileocolic resection. No factors are associated with their development. They are associated with Crohn’s disease recurrence and are persistent.

Download Full-text

The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn’s Disease

Digestion ◽

10.1159/000513589 ◽

2021 ◽

pp. 1-9

Author(s):

Akihiro Yamada ◽

Yuga Komaki ◽

Fukiko Komaki ◽

Haider Haider ◽

Dejan Micic ◽

...

Keyword(s):

Vitamin D ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Postoperative Recurrence ◽

Recurrence Rates ◽

Reactive Protein ◽

Endoscopic Recurrence ◽

Vitamin D Levels ◽

Endoscopic Remission ◽

The University

Background and Aims: Vitamin D deficiency has been associated with disease activity in Crohn’s disease (CD). We assessed whether there is a correlation between vitamin D levels and the risk of postoperative recurrence in CD. Methods: CD patients who underwent surgery were identified from a prospectively maintained database at the University of Chicago. The primary endpoint was the correlation of serum 25-hydroxy vitamin D levels measured at 6–12 months after surgery and the proportion of patients in endoscopic remission, defined as a simple endoscopic score for CD of 0. Clinical, biological (C-reactive protein), and histologic recurrences were also studied. Results: Among a total of 89 patients, 17, 46, and 26 patients had vitamin D levels of <15, 15–30, and >30 ng/mL, respectively. Patients with higher vitamin D levels were significantly more likely to be in endoscopic remission compared to those with lower levels (23, 42, and 67% in ascending tertile order; p = 0.028). On multivariate analysis, vitamin D >30 ng/mL (odds ratio [OR] 0.22, 95% confidence interval [CI] 0.07–0.66, p = 0.006) and anti-tumor necrosis factor agent treatment (OR 0.25, 95% CI 0.08–0.83, p = 0.01) were associated with reduced risk of endoscopic recurrence. Rates of clinical, biological, and histologic remission trended to be higher in patients with higher vitamin D levels (p = 0.17, 0.55, 0.062, respectively). Conclusion: In the present study, higher vitamin D level was associated with lower risk of postoperative endoscopic CD recurrence. Further, studies are warranted to assess the role of vitamin D in postoperative CD recurrence.

Download Full-text